<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Clarke KEN</submitter><pubmed_abstract>&lt;h4>Background and objectives&lt;/h4>Trends in estimates of US pediatric SARS-CoV-2 infection-induced seroprevalence from commercial laboratory specimens may overrepresent children with frequent healthcare needs. We examined seroprevalence trends and compared seroprevalence estimates by testing type and diagnostic coding.&lt;h4>Methods&lt;/h4>Cross-sectional convenience samples of residual sera between September 2021 and February 2022 from 52 U.S. jurisdictions were assayed for infection-induced SARS-CoV-2 antibodies; monthly seroprevalence estimates were calculated by age group. Multivariate logistic analyses compared seroprevalence estimates for specimens associated with ICD-10 codes and laboratory orders indicating well-child care with estimates for other pediatric specimens.&lt;h4>Results&lt;/h4>Infe</pubmed_abstract><journal>The Journal of infectious diseases</journal><pagination>jiac423</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9620360</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical Care-September 2021-February 2022.</pubmed_title><pmcid>PMC9620360</pmcid><pubmed_authors>MacNeil A</pubmed_authors><pubmed_authors>Gundlapalli AV</pubmed_authors><pubmed_authors>Lee A</pubmed_authors><pubmed_authors>Jones J</pubmed_authors><pubmed_authors>Iachan R</pubmed_authors><pubmed_authors>Nycz E</pubmed_authors><pubmed_authors>Kim Y</pubmed_authors><pubmed_authors>Hall A</pubmed_authors><pubmed_authors>Clarke KEN</pubmed_authors><pubmed_authors>Deng Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical Care-September 2021-February 2022.</name><description>&lt;h4>Background and objectives&lt;/h4>Trends in estimates of US pediatric SARS-CoV-2 infection-induced seroprevalence from commercial laboratory specimens may overrepresent children with frequent healthcare needs. We examined seroprevalence trends and compared seroprevalence estimates by testing type and diagnostic coding.&lt;h4>Methods&lt;/h4>Cross-sectional convenience samples of residual sera between September 2021 and February 2022 from 52 U.S. jurisdictions were assayed for infection-induced SARS-CoV-2 antibodies; monthly seroprevalence estimates were calculated by age group. Multivariate logistic analyses compared seroprevalence estimates for specimens associated with ICD-10 codes and laboratory orders indicating well-child care with estimates for other pediatric specimens.&lt;h4>Results&lt;/h4>Infe</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-05T11:57:17.4Z</modification><creation>2025-02-19T03:59:25.305Z</creation></dates><accession>S-EPMC9620360</accession><cross_references><pubmed>36281757</pubmed><doi>10.1093/infdis/jiac423</doi></cross_references></HashMap>